eLife: CAR haNK therapy, targeting PD-L1, effectively de-inhibited, successfully cured 30% of the mice with head and neck cancer. The doctor was bombarded with explosives.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! In recent years, car-t cell therapy has played a powerful therapeutic potential in the field of blood diseases, and has been involved in the treatment of other types of tumor diseases.however, auto car-t cell therapy relies heavily on reprogrammed patient's own T cells to express chimeric antigen receptor (car) targeting tumor cells.at the same time, reprogramming with the patient's own T cells is expensive and laborious.as a result, scientists have developed the "ready-made" cell therapy of natural killer cell hank with high affinity, which not only does not rely on reprogrammed patient's autoimmune cells, but also can mass produce such "ready-made" cells for more patients.however, the immunosuppression of myeloid cells in tumor microenvironment is still a powerful obstacle to effective immunotherapy in many immunotherapies.to solve this problem, Clint Allen, chief researcher of the National Institute of hearing loss and communication impairment (NIDCD), led the research team to carry out a car that can express molecules targeting programmed death ligand 1 (PD-L1, the culprit of immune suppression bone marrow cell mass production to weaken the immune system) The therapeutic effect of hank on human and mouse head and neck cancer was studied, and a control study was conducted (i.e. the therapeutic results of car hank targeting PD-L1 and ordinary hank) were compared.recently, the research was published in eLife, a top international journal, with the title of "engineered killer immune cells target tutors and their immunosuppressive ally".it has been found that car hank, which expresses PD-L1, is more effective in killing tumor cells and can effectively prevent the depletion of hank cells in mice with head and neck tumors.this finding is important because NK cells are usually "depleted" after killing the target cells, while hank cells seem to have the characteristics of "killing".} PD-L1 car hank induces PD-L1 dependent tumor growth inhibition in tumor mice (photo source: Reference 1) in this study, car hank therapy targeting PD-L1 cured 30% of head and neck cancer mice and slowed tumor growth in the rest of the mice without causing toxic reactions.in addition, the treatment also reduced the number of myeloid cells carrying PD-L1 immunosuppressive activity in the tumor microenvironment of mice, and had no effect on other immune enhancing leukocytes.} image source: PD-L1 car hank consumes bone marrow cells with high expression of PD-L1 in peripheral blood of patients with head and neck cancer (photo source: Reference 1). Based on the positive therapeutic effect of mouse experiments, the researchers also cultured cells from patients with advanced head and neck cancer in vitro and conducted the same experiment, and the results also found that PD-L1 was used in the treatment of advanced head and neck cancer After treatment with hank cells, the number of immunosuppressive myeloid cells carrying PD-L1 decreased significantly.this indicates that the treatment can not only directly kill tumor cells, but also remove immunosuppressive myeloid cells that prevent the effectiveness of conventional immunotherapy.these findings suggest that car hank cells expressing PD-L1 can overcome some limitations of conventional immunotherapy relying on T cell activation, and can be used in patients who are not sensitive to or fail in existing immunotherapies.the researchers said that the next step is to introduce the therapy into clinical practice to explore the safety of PD-L1 car hank in patients with advanced or recurrent cancer, and to observe whether the combination of hank cell therapy and other T cell activated immunotherapies can enhance the therapeutic effect.NK cell player behind the research: nantkwest is worth noting that one of the corresponding authors of the study is Patrick soon shiong (Huang Xinxiang), who is the chairman and CEO of nantkwest abroad.} Huang Xinxiang (image source: Iread MED) in the past two years, nantkwest company has started the research on NK cell combination therapy, and has developed a proprietary "off the shelf" NK platform; according to the literature, the hank cells in this study were provided by the company. in addition, the company's relevant therapeutic research has always been paid close attention by the medical maker. according to the company's current R & D pipeline, four of the eight research projects have entered phase II clinical stage, which are respectively used for the treatment of triple negative breast cancer, Merkel cell cancer, squamous cell carcinoma and pancreatic cancer. } part of the pipeline diagram of nantkwest company (photo source: reference 2) using its unique "off the shelf" NK platform, nantkwest designed NK cells to induce cell death against cancer and virus infection through several mechanisms, including: 1. Congenital killing. therefore, NK platform can recognize stress proteins on cancer cells, and these proteins will release toxic particles after binding, which will immediately kill the target cells. 2. Hank platform: killing cells with antibody mediated. the platform has been engineered to express antibody receptors that can bind to therapeutic antibody products, thus enhancing the cancer cell killing effect of the antibody. 3. Tank platform: targeted killing with car. NK cells of this platform were engineered to express car to target tumor specific antigens found on the surface of cancer cells. } image source: Dr. nantkwest Huang Xinxiang once said: "we hypothesized that the universal treatment scheme of NK cells and T cells can effectively treat a variety of cancer types, and has been preliminarily confirmed. "recommended reading: NK cell therapy combined with PD-L1 inhibitor and IL-15 agonist, nantkwest for the first solid tumor patients| With the release of car-nk clinical data of nantkwest targeting PD-L1 / CD16, the company has made a huge disclosure: ind, a new NK cell therapy specific for solid tumors, has been approved as the first case of pancreatic cancer patients who have been completely relieved by the "moon landing plan"! Car-nk combined with IL-15 super agonist implements the "triangle attack" strategy. Mai Meng reveals that nantkwest and promab develop BCMA car-nk therapy, and the prospect of multiple myeloma treatment is becoming more and more bright, occupying the technical highland! Nantkwest announced the early clinical results of a new memory immunotherapy vaccine. Various advanced solid tumors are called "Yi Mai Meng". It focuses on four popular biomedical fields, including tumor immunity, new antibodies, stem cell regeneration medicine and gene therapy. 2020 bpit Biopharmaceutical innovation and technology conference will be held in Nanjing International Youth Culture Center on July 19-21, 2020! Click the picture above to view the agenda of the conference